冠心病患者中纤溶酶原激活物抑制剂-1 4G/5G多态性与心源性猝死

PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.

作者信息

Anvari A, Schuster E, Gottsauner-Wolf M, Wojta J, Huber K

机构信息

Department of Cardiology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

出版信息

Thromb Res. 2001 Jul 15;103(2):103-7. doi: 10.1016/s0049-3848(01)00277-8.

DOI:10.1016/s0049-3848(01)00277-8

PMID:11457467

Abstract

UNLABELLED

The 4G/5G polymorphism of the plasminogen activator inhibitor type I (PAI-I) gene is involved in coronary artery disease (CAD), with the highest risk in 4G/4G homozygotes. The role of PAI-I polymorphism in patients suffering from CAD and history of sudden cardiac death (SCD) has not been addressed yet. We studied the frequency distribution of the PAI-I gene to test the hypothesis that the 4G/4G genotype favors myocardial ischemia and, even in the absence of acute infarction, promotes SCD in patients with CAD.

METHODS

The PAI-I 4G/5G genotypes and PAI-I antigen plasma levels were determined in 97 patients with CAD and a history of SCD treated with an implantable cardioverter defibrillator (ICD) (defibrillator group) comparing to 113 patients with CAD but no history of SCD (control group).

RESULTS

The defibrillator group consisted of significantly more 4G/4G homozygotes and higher PAI-I levels than the control group (44% vs. 24%, 173+/-41 vs. 144+/-49 ng/ml; P<.01). The carriers of 4G allele had a significantly higher risk for SCD (odds ratio (OR) 1.9) with the highest risk in the 4G/4G genotype (OR 3.6, P<.01).

CONCLUSION

These results suggest that the PAI-I 4G/4G genotype is associated with SCD in patients suffering from CAD.

摘要

未标注

纤溶酶原激活物抑制剂I型（PAI-I）基因的4G/5G多态性与冠状动脉疾病（CAD）有关，4G/4G纯合子的风险最高。PAI-I多态性在患有CAD且有心脏性猝死（SCD）病史的患者中的作用尚未得到研究。我们研究了PAI-I基因的频率分布，以检验以下假设：4G/4G基因型易患心肌缺血，即使在没有急性梗死的情况下，也会促进CAD患者发生SCD。